Psoriatic Arthritis for Anti-Rheumatic Drug Patients

A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs

elderly man's hands


AGE: 18+ years old
TYPE: Investigational Treatment Study
CONDITION: Psoriasis
LOCATION: University Hospitals Medical Centers

Learn More About This Research Study

For more information, please contact study coordinator, Amy Johnson, MD at 216-286-7369 or complete the form below.

Study Purpose

The purpose of this study is to evaluate the efficacy and safety of deucravacitinib versus placebo in participants with active psoriatic arthritis who are naïve to biologic disease-modifying anti-rheumatic drugs. The long term extension period will provide additional long-term efficacy and safety information.

Who Can Participate

Participants diagnosed to have psoriatic arthritis (PsA) of at least 3 months duration at screening may be eligible for this study.

Request More Information

To learn more about this study, please fill out the form below to request more information.